Desmopressin vs Terlipressin — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
Desmopressin (DDAVP) is a synthetic analogue of vasopressin (ADH) with two key modifications: deamination of the N-terminal cysteine and substitution of L-arginine with D-arginine at position 8. These changes dramatically increase V2 receptor selectivity (antidiuretic action) ove...
Calculate Desmopressin dose →Terlipressin is a synthetic prodrug analogue of vasopressin (ADH), featuring a triglycine extension at the N-terminus of lysine-8-vasopressin. After IV administration, plasma enzymes cleave the triglycine moiety to release the active metabolite lysine-vasopressin, providing a slo...
Calculate Terlipressin dose →| Parameter | Desmopressin | Terlipressin |
|---|---|---|
| Category | Vasopressin Analogue | Vasopressin Analogue |
| Research | FDA Approved (multiple indications) | FDA Approved (2022) |
| Half-Life | ~1.5-2.5 hours IV; ~3-4 hours intranasal; 6-8 hours oral | ~6 hours (active metabolite Lys8-VP) |
| Typical Dose | 10-40 mcg intranasal; 0.1-0.4 mg oral; 0.3 mcg/kg IV (hemostasis) | 1-2 mg IV q4-6h (variceal bleeding); 1 mg IV q6h (HRS) |
| Frequency | Once to three times daily (depending on indication) | Every 4-6 hours IV bolus or continuous infusion |
| Route | Intranasal, oral, SC, IV | IV bolus or continuous infusion |
| FDA Status | FDA approved for DI, primary nocturnal enuresis, von Willebrand disease type 1, hemophilia A | FDA approved 2022 for hepatorenal syndrome type 1 (Terlivaz) |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.